Literature DB >> 32990929

Linking chronic kidney disease and Parkinson's disease: a literature review.

Jesús D Meléndez-Flores1,2, Ingrid Estrada-Bellmann3,4.   

Abstract

Chronic kidney disease (CKD) has been typically implicated in cardiovascular risk, considering the function the kidney has related to blood pressure, vitamin D, red blood cell metabolism, and electrolyte and acid-base regulation. However, neurological consequences are also attributed to this disease. Among these, recent large epidemiological studies have demonstrated an increased risk for Parkinson's disease (PD) in patients with CKD. Multiple studies have evaluated individually the association of blood pressure, vitamin D, and red blood cell dysmetabolism with PD, however, no study has reviewed the potential mechanisms related to these components in context of CKD and PD. In this review, we explored the association of CKD and PD and linked the components of the former to propose potential pathways explaining a future increased risk for PD, where renin-angiotensin system, oxidative stress, and inflammation have a main role. Potential preventive and therapeutic interventions based on these associations are also explored. More preclinical studies are needed to confirm the potential link of CKD conditions and future PD risk, whereas more interventional studies targeting this association are warranted to confirm their potential benefit in PD.

Entities:  

Keywords:  Anemia; Chronic kidney disease; Oxidative stress; Parkinson’s disease; Renin-angiotensin system

Year:  2020        PMID: 32990929     DOI: 10.1007/s11011-020-00623-1

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  137 in total

Review 1.  Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease.

Authors:  Hussien Ahmed; Mohamed Gadelkarim; Mahmoud Morsi; Kamal Awad; Mohamed Elnenny; Esraa Ghanem; Shaimaa El-Jaafary; Ahmed Negida
Journal:  CNS Neurol Disord Drug Targets       Date:  2017       Impact factor: 4.388

2.  Oxidative stress markers in pre-uremic patients.

Authors:  M Annuk; B Fellström; O Akerblom; K Zilmer; T Vihalemm; M Zilmer
Journal:  Clin Nephrol       Date:  2001-10       Impact factor: 0.975

Review 3.  Mechanisms of anemia in CKD.

Authors:  Jodie L Babitt; Herbert Y Lin
Journal:  J Am Soc Nephrol       Date:  2012-08-30       Impact factor: 10.121

4.  Clinical measures identify vitamin D deficiency in dialysis.

Authors:  Ishir Bhan; Sherri-Ann M Burnett-Bowie; Jun Ye; Marcello Tonelli; Ravi Thadhani
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

5.  Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease.

Authors:  Damien R Ashby; Daniel P Gale; Mark Busbridge; Kevin G Murphy; Neill D Duncan; Tom D Cairns; David H Taube; Stephen R Bloom; Frederick W K Tam; Richard S Chapman; Patrick H Maxwell; Peter Choi
Journal:  Kidney Int       Date:  2009-02-11       Impact factor: 10.612

6.  Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States.

Authors:  Rajiv Agarwal; Allen R Nissenson; Daniel Batlle; Daniel W Coyne; J Richard Trout; David G Warnock
Journal:  Am J Med       Date:  2003-09       Impact factor: 4.965

7.  Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier.

Authors:  Vinicia Campana Biancardi; Sook Jin Son; Sahra Ahmadi; Jessica A Filosa; Javier E Stern
Journal:  Hypertension       Date:  2013-12-16       Impact factor: 10.190

Review 8.  Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology.

Authors:  Masato Asahina; Ekawat Vichayanrat; David A Low; Valeria Iodice; Christopher J Mathias
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-09-01       Impact factor: 10.154

Review 9.  Angiotensin II revisited: new roles in inflammation, immunology and aging.

Authors:  Ariela Benigni; Paola Cassis; Giuseppe Remuzzi
Journal:  EMBO Mol Med       Date:  2010-07       Impact factor: 12.137

Review 10.  Neurological complications in chronic kidney disease.

Authors:  Ria Arnold; Tushar Issar; Arun V Krishnan; Bruce A Pussell
Journal:  JRSM Cardiovasc Dis       Date:  2016-11-03
View more
  4 in total

Review 1.  GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight.

Authors:  Giulia Monti; Diana Gomes Moreira; Mette Richner; Henricus Antonius Maria Mutsaers; Nelson Ferreira; Asad Jan
Journal:  Cells       Date:  2022-06-25       Impact factor: 7.666

Review 2.  Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?

Authors:  Sophie Liabeuf; Marion Pepin; Casper F M Franssen; Davide Viggiano; Sol Carriazo; Ron T Gansevoort; Loreto Gesualdo; Gaye Hafez; Jolanta Malyszko; Christopher Mayer; Dorothea Nitsch; Alberto Ortiz; Vesna Pešić; Andrzej Wiecek; Ziad A Massy
Journal:  Nephrol Dial Transplant       Date:  2021-12-28       Impact factor: 5.992

3.  Mercury is present in neurons and oligodendrocytes in regions of the brain affected by Parkinson's disease and co-localises with Lewy bodies.

Authors:  Roger Pamphlett; David P Bishop
Journal:  PLoS One       Date:  2022-01-11       Impact factor: 3.240

4.  Parkinson's Disease Etiology: Insights and Associations with Phosphate Toxicity.

Authors:  Ronald B Brown
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.